21.03.2013 • News

Catalent Australia, Medipharm Form Partnership

Catalent Pharma Solutions today announced that it will apply its drug delivery technology for the launch of three new products for Malaysian natural healthcare supplier, Medipharm Industries. Catalent has worked together with Medipharm to quickly develop new formulations for Medipharm's recently launched Eurobio Vibrex Zinc-Plus, Bio-Vizmax and Bio-SMEDDS Q10 products for the Malaysian market and will now act as sole supply partner.

Eurobio Vibrex Zinc-Plus is an advanced formula containing zinc and other essential nutrients designed to provide complete support for skin, hair and nail health, men's health, immunity and vitality. Bio-Vizmax provides eye nutrition and is formulated with clinically tested Lutein and Zeaxanthin for eye/vision health, while Bio-SMEDDS CoQ10 is being marketed to general practitioners and cardiologists in 50mg capsules for heart health and organ function. Catalent manufactures the products at its Braeside facility, near Melbourne, Australia. All products are manufactured to the highest cGMP and cGLP pharmaceutical standards.

 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.